ISSN:
1569-8041
Keywords:
cisplatin
;
ovarian cancer
;
paclitaxel
;
sequential chemotherapy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Purpose:To examine the activity and safety of two sequentiallyscheduled chemotherapy regimens comprising four cycles of paclitaxel (pctx)200 mg/m2/3 hours then four cycles of cisplatin (cisDDP) 100mg/m2, and vice versa, in patients with previouslyuntreated advanced ovarian cancer. Patients and methods:Between January 1994 and February 1996, werecruited 30 patients to the pctx-then-cisDDP regimen and 29 tocisDDP-then-pctx, in parallel phase II trials. Results:Both regimens were predictably active with responses seenin 22 of 30 patients (OR 74%; CR 27%, PR 47%) treatedwith pctx-then-cisDDP, as against 13 of 21 patients (OR 62%; CR38%, PR 24%) treated with cisDDP-then-pctx. The OR rate to fourcycles of pctx (induction) was 43%, with 27% diseaseprogression; the OR to four cycles of cisDDP (induction) was 57%, with5% progression. However, progression rates across both induction andconsolidation phases were 16% (pctx-then-cisDDP) and 29%(cisDDP-then-pctx). Both regimens were unacceptably neurotoxic, 11 patientssuffering grade 3 sensory neurotoxicity (5 on pctx-then-cisDDP, 6 oncisDDP-then-pctx) and 20 having grade 3 deafness (9 on pctx-then-cisDDP, 11on cisDDP-then-pctx). Conclusion:The activity of these sequential regimens justifiestheir further development using the less neurotoxic platinum analoguecarboplatin, perhaps combining paclitaxel with other platinum non-crossresistant drugs.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008343519687
Permalink
